A neutralizing VEGF antibody prevents glomerular hypertrophy in a model of obese type 2 diabetes, the Zucker diabetic fatty rat

Bieke F. Schrijvers, Allan Flyvbjerg, Ronald Tilton, Norbert H. Lameire, An S. De Vriese

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Background. Antagonism of vascular endothelial growth factor (VEGF) has improved the outcome in experimental nephropathies of various origins, including diabetic nephropathy in a type 1 diabetic rat model and a type 2 diabetic mouse model. Neutralizing VEGF antibodies prevented glomerular hypertrophy in these models. We examined the renal effects of VEGF blockade in an obese rat model of type 2 diabetic nephropathy and investigated the mechanism underlying the inhibition of glomerular hypertrophy. Methods. Twenty female Zucker diabetic fatty (ZDF) rats, fed a high-fat diet and aged 10 weeks, were treated with VEGF antibodies or an irrelevant isotype-matched IgG. Ten heterozygous (fa/+) littermates served as additional non-diabetic, lean controls. Urinary albumin excretion (UAE) and creatinine clearance (CrCl) were assessed at baseline, and at 3 and 5 weeks. Kidney weight and glomerular volume were determined at the end of the study. Glomerular apoptosis was examined with anti-active caspase-3 immunohistochemistry. Results. All obese animals had established diabetes, hyperlipidaemia and normal blood pressure, which were not influenced by VEGF antibody treatment. ZDF control rats had increased UAE, CrCl, kidney weights and glomerular volumes compared with non-diabetic, lean control rats. VEGF antibody treatment prevented the glomerular hypertrophy, but did not affect UAE, CrCl and kidney weight. Glomerular anti-active caspase-3 immunostaining was not different between the groups. Conclusions. Inhibition of VEGF prevented early glomerular hypertrophy in ZDF rats with established diabetes. Increased apoptosis of glomerular endothelial cells does not appear to underly the inhibition of glomerular growth.

Original languageEnglish (US)
Pages (from-to)324-329
Number of pages6
JournalNephrology Dialysis Transplantation
Volume21
Issue number2
DOIs
StatePublished - Feb 2006

Fingerprint

Type 2 Diabetes Mellitus
Hypertrophy
Vascular Endothelial Growth Factor A
Antibodies
Kidney
Albumins
Creatinine
Diabetic Nephropathies
Weights and Measures
Caspase 3
Apoptosis
High Fat Diet
Hyperlipidemias
Endothelial Cells
Immunoglobulin G
Immunohistochemistry
Blood Pressure
Therapeutics
Growth

Keywords

  • Creatinine clearance
  • Diabetes
  • Glomerular volume
  • Urinary albumin excretion
  • Vascular endothelial growth factor
  • Zucker diabetic fatty rats

ASJC Scopus subject areas

  • Nephrology
  • Transplantation

Cite this

A neutralizing VEGF antibody prevents glomerular hypertrophy in a model of obese type 2 diabetes, the Zucker diabetic fatty rat. / Schrijvers, Bieke F.; Flyvbjerg, Allan; Tilton, Ronald; Lameire, Norbert H.; De Vriese, An S.

In: Nephrology Dialysis Transplantation, Vol. 21, No. 2, 02.2006, p. 324-329.

Research output: Contribution to journalArticle

Schrijvers, Bieke F. ; Flyvbjerg, Allan ; Tilton, Ronald ; Lameire, Norbert H. ; De Vriese, An S. / A neutralizing VEGF antibody prevents glomerular hypertrophy in a model of obese type 2 diabetes, the Zucker diabetic fatty rat. In: Nephrology Dialysis Transplantation. 2006 ; Vol. 21, No. 2. pp. 324-329.
@article{87008743772e4d079c3ff60bf1662f8b,
title = "A neutralizing VEGF antibody prevents glomerular hypertrophy in a model of obese type 2 diabetes, the Zucker diabetic fatty rat",
abstract = "Background. Antagonism of vascular endothelial growth factor (VEGF) has improved the outcome in experimental nephropathies of various origins, including diabetic nephropathy in a type 1 diabetic rat model and a type 2 diabetic mouse model. Neutralizing VEGF antibodies prevented glomerular hypertrophy in these models. We examined the renal effects of VEGF blockade in an obese rat model of type 2 diabetic nephropathy and investigated the mechanism underlying the inhibition of glomerular hypertrophy. Methods. Twenty female Zucker diabetic fatty (ZDF) rats, fed a high-fat diet and aged 10 weeks, were treated with VEGF antibodies or an irrelevant isotype-matched IgG. Ten heterozygous (fa/+) littermates served as additional non-diabetic, lean controls. Urinary albumin excretion (UAE) and creatinine clearance (CrCl) were assessed at baseline, and at 3 and 5 weeks. Kidney weight and glomerular volume were determined at the end of the study. Glomerular apoptosis was examined with anti-active caspase-3 immunohistochemistry. Results. All obese animals had established diabetes, hyperlipidaemia and normal blood pressure, which were not influenced by VEGF antibody treatment. ZDF control rats had increased UAE, CrCl, kidney weights and glomerular volumes compared with non-diabetic, lean control rats. VEGF antibody treatment prevented the glomerular hypertrophy, but did not affect UAE, CrCl and kidney weight. Glomerular anti-active caspase-3 immunostaining was not different between the groups. Conclusions. Inhibition of VEGF prevented early glomerular hypertrophy in ZDF rats with established diabetes. Increased apoptosis of glomerular endothelial cells does not appear to underly the inhibition of glomerular growth.",
keywords = "Creatinine clearance, Diabetes, Glomerular volume, Urinary albumin excretion, Vascular endothelial growth factor, Zucker diabetic fatty rats",
author = "Schrijvers, {Bieke F.} and Allan Flyvbjerg and Ronald Tilton and Lameire, {Norbert H.} and {De Vriese}, {An S.}",
year = "2006",
month = "2",
doi = "10.1093/ndt/gfi217",
language = "English (US)",
volume = "21",
pages = "324--329",
journal = "Nephrology Dialysis Transplantation",
issn = "0931-0509",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - A neutralizing VEGF antibody prevents glomerular hypertrophy in a model of obese type 2 diabetes, the Zucker diabetic fatty rat

AU - Schrijvers, Bieke F.

AU - Flyvbjerg, Allan

AU - Tilton, Ronald

AU - Lameire, Norbert H.

AU - De Vriese, An S.

PY - 2006/2

Y1 - 2006/2

N2 - Background. Antagonism of vascular endothelial growth factor (VEGF) has improved the outcome in experimental nephropathies of various origins, including diabetic nephropathy in a type 1 diabetic rat model and a type 2 diabetic mouse model. Neutralizing VEGF antibodies prevented glomerular hypertrophy in these models. We examined the renal effects of VEGF blockade in an obese rat model of type 2 diabetic nephropathy and investigated the mechanism underlying the inhibition of glomerular hypertrophy. Methods. Twenty female Zucker diabetic fatty (ZDF) rats, fed a high-fat diet and aged 10 weeks, were treated with VEGF antibodies or an irrelevant isotype-matched IgG. Ten heterozygous (fa/+) littermates served as additional non-diabetic, lean controls. Urinary albumin excretion (UAE) and creatinine clearance (CrCl) were assessed at baseline, and at 3 and 5 weeks. Kidney weight and glomerular volume were determined at the end of the study. Glomerular apoptosis was examined with anti-active caspase-3 immunohistochemistry. Results. All obese animals had established diabetes, hyperlipidaemia and normal blood pressure, which were not influenced by VEGF antibody treatment. ZDF control rats had increased UAE, CrCl, kidney weights and glomerular volumes compared with non-diabetic, lean control rats. VEGF antibody treatment prevented the glomerular hypertrophy, but did not affect UAE, CrCl and kidney weight. Glomerular anti-active caspase-3 immunostaining was not different between the groups. Conclusions. Inhibition of VEGF prevented early glomerular hypertrophy in ZDF rats with established diabetes. Increased apoptosis of glomerular endothelial cells does not appear to underly the inhibition of glomerular growth.

AB - Background. Antagonism of vascular endothelial growth factor (VEGF) has improved the outcome in experimental nephropathies of various origins, including diabetic nephropathy in a type 1 diabetic rat model and a type 2 diabetic mouse model. Neutralizing VEGF antibodies prevented glomerular hypertrophy in these models. We examined the renal effects of VEGF blockade in an obese rat model of type 2 diabetic nephropathy and investigated the mechanism underlying the inhibition of glomerular hypertrophy. Methods. Twenty female Zucker diabetic fatty (ZDF) rats, fed a high-fat diet and aged 10 weeks, were treated with VEGF antibodies or an irrelevant isotype-matched IgG. Ten heterozygous (fa/+) littermates served as additional non-diabetic, lean controls. Urinary albumin excretion (UAE) and creatinine clearance (CrCl) were assessed at baseline, and at 3 and 5 weeks. Kidney weight and glomerular volume were determined at the end of the study. Glomerular apoptosis was examined with anti-active caspase-3 immunohistochemistry. Results. All obese animals had established diabetes, hyperlipidaemia and normal blood pressure, which were not influenced by VEGF antibody treatment. ZDF control rats had increased UAE, CrCl, kidney weights and glomerular volumes compared with non-diabetic, lean control rats. VEGF antibody treatment prevented the glomerular hypertrophy, but did not affect UAE, CrCl and kidney weight. Glomerular anti-active caspase-3 immunostaining was not different between the groups. Conclusions. Inhibition of VEGF prevented early glomerular hypertrophy in ZDF rats with established diabetes. Increased apoptosis of glomerular endothelial cells does not appear to underly the inhibition of glomerular growth.

KW - Creatinine clearance

KW - Diabetes

KW - Glomerular volume

KW - Urinary albumin excretion

KW - Vascular endothelial growth factor

KW - Zucker diabetic fatty rats

UR - http://www.scopus.com/inward/record.url?scp=31544433941&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=31544433941&partnerID=8YFLogxK

U2 - 10.1093/ndt/gfi217

DO - 10.1093/ndt/gfi217

M3 - Article

C2 - 16249198

AN - SCOPUS:31544433941

VL - 21

SP - 324

EP - 329

JO - Nephrology Dialysis Transplantation

JF - Nephrology Dialysis Transplantation

SN - 0931-0509

IS - 2

ER -